Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NT-219 by Purple Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Recurrent Head And Neck Squamous Cell...
NT-219 by Purple Biotech for Breast Cancer: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
NT-219 by Purple Biotech for Metastatic Colorectal Cancer: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
NT-219 by Purple Biotech for Solid Tumor: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
NT-219 by Purple Biotech for Pancreatic Cancer: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
NT-219 by Purple Biotech for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...